Novo Nordisk's Wegovy® Pill Approved by FDA, Shows 16.6% Weight Loss
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2h ago
0mins
Source: Globenewswire
- Clinical Trial Success: In the OASIS 4 trial, the Wegovy® pill demonstrated a mean weight loss of 16.6% among 307 adults with obesity or overweight, confirming its efficacy comparable to the injectable Wegovy®, thereby reinforcing Novo Nordisk's leadership in the weight management market.
- FDA Approval: The Wegovy® pill has received FDA approval as the first oral GLP-1 receptor agonist, marking a significant innovation in obesity treatment, with plans for a US launch in January 2026 to meet the growing market demand.
- Significant Market Potential: Novo Nordisk anticipates that the Wegovy® pill will provide a convenient treatment option for obesity patients, especially given that one in three trial participants achieved a weight loss of 20% or more, which will significantly enhance patient quality of life and drive sales growth for the company.
- Global Expansion Plans: Novo Nordisk has submitted applications for the Wegovy® pill to the European Medicines Agency, demonstrating its commitment to global market expansion and expected to further enhance its competitiveness in international markets.
NVO
$48.1+Infinity%1D
Analyst Views on NVO
Wall Street analysts forecast NVO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVO is 57.37 USD with a low forecast of 47.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
4 Buy
2 Hold
1 Sell
Moderate Buy
Current: 48.090
Low
47.00
Averages
57.37
High
70.00
Current: 48.090
Low
47.00
Averages
57.37
High
70.00
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
